St. Jude Reference #SJ-18-0019
Researchers at St. Jude have invented a novel way to expand chimeric antigen receptor (CAR) T cells that work better for gene therapy. These T cells could form the basis of the next generation of CAR therapies that provide sustainable, superior antitumor activity.
Incorporating IL-12 in in vitro culture conditions results in the generation of stem cell memory (Tscm) cells, which possess an enhanced ability to eradicate tumors without reaching exhaustion.
cer, immunology, chimeric antigen receptor (CAR), T cell, stem cell memory (Tscm) cells, epigenetic, IL-12, expansion
Granted patents or published applications
Pending PCT, published as WO 2020/012331.
Related scientific references
Brooke Prinzing et al, Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity, Science Translational Medicine (2021). DOI: 10.1126/scitranslmed.abh0272
St. Jude is seeking a partner or partners to help develop this for use with therapies. Contact: email@example.com
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.